Pakistan's federal cabinet raises concerns over vaccine pricing and monopolistic practices, forms committee to determine fair prices for locally manufactured vaccines and ensure compliance with international standards.
The federal cabinet has expressed serious concerns over the pricing of locally manufactured vaccines and the potential for monopolistic practices by pharmaceutical companies in Pakistan. During a meeting chaired by Prime Minister Shehbaz Sharif, the cabinet gave in-principle approval to the National Policy for Advancing Indigenous Vaccine Production, which aims to promote local vaccine production and reduce dependence on imported vaccines.
The cabinet also formed a committee to make recommendations for determining the prices of locally manufactured vaccines and to examine the factors that determine the costs of production. The committee will study international best practices for pricing vaccines and propose a fair pricing model to prevent excessive profiteering by the proposed National Vaccine Alliance, a consortium of pharmaceutical firms that will be responsible for indigenous vaccine production.
The cabinet members emphasized the need to ascertain the costing and pricing model that the National Vaccine Alliance would follow, particularly since the government has agreed to provide a buyback guarantee for locally manufactured vaccines. They the alliance would essentially function as a monopoly, and it was imperative to ensure that it did not charge exorbitant prices to the detriment of vaccine users. The cabinet members also stressed the need for capacity building of the Drug Regulatory Authority of Pakistan (DRAP) to effectively monitor vaccine pricing and ensure compliance with international standards set by the World Health Organization (WHO).
Minister for National Health Services Mustafa Kamal responded to the cabinet members' concerns, explaining that high production costs, particularly research and development outlays, made it difficult for pharmaceutical companies to produce vaccines without suitable incentives. He the global economic model for vaccine production involved forming alliances of several pharmaceutical companies to achieve economies of scale and ensure profitability. The minister assured the cabinet that under the draft National Policy for Advancing Indigenous Vaccine Production, the alliance's vaccine pricing would be subject to regulation by DRAP, which would ensure that vaccines are available to the public at reasonable prices.
The formation of the committee and the emphasis on fair pricing and regulation are significant steps towards promoting transparency and accountability in the vaccine production sector in Pakistan. The government's efforts to support local vaccine production and reduce dependence on imported vaccines are crucial for improving public health outcomes and ensuring access to affordable healthcare for all citizens. As the committee begins its work, it is essential to ensure that the interests of vaccine users are protected, and that the National Vaccine Alliance operates in a fair and transparent manner.
